Paroxysmal hemicrania: a rare headache that still deserves the whole evaluation.

Short, savage attacks of pain around one eye have a name and a specific treatment. If the name does not quite fit, or the treatment does not quite work, read on.

This page is about understanding the condition and the role the brain and nervous system can play in it. It is not a diagnosis. Your own clinicians know your case.

What paroxysmal hemicrania is

Paroxysmal hemicrania is one of a small group of headache disorders called trigeminal autonomic cephalalgias, or TACs. The family also includes cluster headache and hemicrania continua.

The attacks are brief, typically a few minutes to half an hour, severe, and strictly one-sided, centred in or around the eye or temple. They come many times a day, sometimes dozens, and are accompanied on the same side by a red or watery eye, a blocked or running nostril, a drooping or swollen eyelid or facial sweating.

Its defining feature is a complete response to indomethacin, an anti-inflammatory drug. If the attacks stop entirely on an adequate dose, the diagnosis is confirmed. If they do not, the diagnosis is, by definition, in question. The condition is thought to involve the hypothalamus and the brain's pain pathways rather than any damage to the face or eye.

The neuroplastic contribution

Neuroplastic symptoms are real symptoms generated by learned pathways in the brain and nervous system rather than by ongoing damage in the body. They are not imaginary and not 'all in your head' in the dismissive sense; they are a sensitized alarm system producing real pain, and because the brain can change, that sensitization can be reduced.

The ATNS Index of Neuroplastic Symptoms is appropriately cautious about paroxysmal hemicrania. It does not say the condition is neuroplastic. It says neuroplastic symptoms could be a contributing factor and should be assessed as part of a complete evaluation. Several features make that a reasonable position:

• Paroxysmal hemicrania is already understood as a disorder of the brain's own pain and autonomic circuits, not of the face. The line between a primary headache generated by the brain and a neuroplastic symptom generated by the brain is not a sharp one.
• The diagnosis depends on a treatment response. When indomethacin helps only partly, or stops helping, or cannot be tolerated, the person is left with one-sided head pain that may fit other patterns better, including a sensitized trigeminal system.

The index asks for the neuroplastic question to be included, not substituted: get the diagnosis right, do the indomethacin trial properly, and also look at what the nervous system has learned along the way. Our explainer on central sensitization describes that learning.

What the research shows

We want to be straightforward about the evidence for this specific condition. Paroxysmal hemicrania is rare, and its research consists of reviews, case series and case reports. What that research shows clearly is that it is a disorder of the brain's own circuits.

• A clinical review of paroxysmal hemicrania describes functional imaging showing activation of the posterior hypothalamus, as in the other trigeminal autonomic cephalalgias. That activation was present during spontaneous attacks and in pain-free periods between them, but not once attacks had been stopped with indomethacin.
• A more recent update on the condition describes a 'permissive' central role for the hypothalamus based on functional imaging studies, meaning the brain sets the conditions in which attacks can fire.
• A retrospective study of a consecutive series of 22 patients, which also critically analysed the diagnostic criteria, illustrates how much real-world cases vary and why the criteria, including the indomethacin response, deserve careful application.

None of these studies examined neuroplastic or psychological contributions, and we found no controlled data on stress, fear or mood in this condition. So the honest summary is that paroxysmal hemicrania is a real, specific, brain-based headache disorder with a specific treatment; that brain imaging shows its circuits staying active between attacks; and that any added neuroplastic contribution is plausible but unstudied. The ATNS index's call to include it in a complete evaluation is a sensible precaution rather than an established finding.

Signs the brain may be part of the picture

• Indomethacin gave partial relief, or relief that faded, rather than the complete response that defines the condition.
• Pain continues between attacks as a background ache, or has spread to the other side or the neck.
• Attacks cluster around stressful periods, poor sleep or emotional events.
• Fear of the next attack dominates your day, and you have stopped activities to avoid triggering one.

A solution that addresses it

Where a neuroplastic contribution is suspected, there is an approach that addresses the brain's role: pain reprocessing. It combines education about neuroplastic symptoms, somatic tracking (observing the sensation in and around the eye with curiosity rather than dread, particularly between attacks), reducing fear and the sense of threat that each attack leaves behind, a graded return to avoided activities, emotional awareness and expression, and acceptance and commitment skills. Trained clinicians deliver it, and digital programs increasingly make it available. It is an addition to headache-specialist care, never a replacement for it.

Cindra is a daily AI companion built around these approaches, with daily check-ins, short practices and plain-language lessons, for people whose symptoms have a neuroplastic component. If your attacks have a name and your life is still ruled by them, you can join the waitlist.

What to do next

1. Make sure you are under the care of a neurologist or headache specialist. Paroxysmal hemicrania is rare enough that general clinicians may not recognise it, and the differential includes cluster headache, hemicrania continua, trigeminal neuralgia and, occasionally, structural causes that imaging must exclude.
2. Ask whether your indomethacin trial was adequate in dose and duration, and what your response actually was. A complete response confirms the diagnosis; anything less reopens it.
3. Ask that neuroplastic symptoms be assessed as part of the complete evaluation, especially for pain between attacks and for the fear that surrounds them.
4. If a contribution seems likely, start learning and practising. Our guide to the fear-avoidance cycle is directly relevant to attack-related dread.

Seek urgent care for a sudden, severe headache unlike your usual attacks, a headache with fever and stiff neck, weakness, numbness, confusion, or a change in vision that does not settle with the attack. Do not stop prescribed medication without your specialist's advice.

This article is for general education and is not medical advice, and it does not diagnose or treat any condition. Persistent symptoms deserve a proper medical assessment to rule out disease or injury before a neuroplastic explanation is considered. If your symptoms are new, changing, or come with red-flag signs such as fever, unexplained weight loss, numbness or weakness, chest pain, or loss of bladder or bowel control, see a clinician promptly.